William Boreland

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.

Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.

Journal: Haematologica
Published: June 02, 2026

Fecal microbiota transplantation in the treatment of acute graft-versus-host disease: A retrospective study performed by the Complications Working Party and Pediatric Diseases Working Party of the EBMT.

Fecal microbiota transplantation in the treatment of acute graft-versus-host disease: A retrospective study performed by the Complications Working Party and Pediatric Diseases Working Party of the EBMT.

Journal: Bone marrow transplantation
Published: February 07, 2026

Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party.

Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party.

Journal: Cancers
Published: December 02, 2025

Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party.

Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party.

Journal: Bone marrow transplantation
Published: April 11, 2025

Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party.

Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party.

Journal: Bone marrow transplantation
Published: March 14, 2025

Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT.

Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT.

Journal: Bone marrow transplantation
Published: March 11, 2025

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Journal: Blood cancer journal
Published: February 26, 2025

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT.

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT.

Journal: Bone marrow transplantation
Published: February 06, 2025

Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.

Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.

Journal: Bone marrow transplantation
Published: October 18, 2024

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party.

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party.

Journal: Leukemia
Published: October 01, 2024

Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party.

Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party.

Journal: Bone marrow transplantation
Published: September 07, 2024

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.

Journal: Leukemia
Published: September 04, 2024
Showing 1-12 of 20

Last Updated: 09/26/2026